Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs

Paul Schloesser

Associate Editor

Nine months after Affinia Therapeutics raised $110 million in a Series B, the biotech has set its eyes on the Nasdaq.

The MA-based preclinical gene therapy biotech, which got $60 million in startup capital from New Enterprise Associates, F-Prime and Atlas in 2019, filed an S-1 with the SEC on Tuesday, announcing initial plans to go public and penciling in a $100 million raise. Affinia plans to list under the ticker $AFTX.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...

Gene ther­a­py play­er Affinia aims to go pub­lic, hop­ing to raise big mon­ey in ef­fort to re­make AAVs

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal ...

Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...